Cubist Systematic Strategies’s Novavax NVAX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $1.92M | Sell |
221,540
-492,146
| -69% | -$3.83M | 0.01% | 1593 |
|
|
2025
Q2 | $4.5M | Buy |
+713,686
| New | +$4.73M | 0.02% | 1077 |
|
|
2023
Q3 | – | Sell |
-301
| Closed | -$2.24K | – | 3755 |
|
|
2023
Q2 | $2.24K | Sell |
301
-52,746
| -99% | -$415K | ﹤0.01% | 3350 |
|
|
2023
Q1 | $368K | Sell |
53,047
-437,703
| -89% | -$4.03M | ﹤0.01% | 2857 |
|
|
2022
Q4 | $5.04M | Buy |
490,750
+471,178
| +2,407% | +$8.32M | 0.03% | 1009 |
|
|
2022
Q3 | $356K | Sell |
19,572
-6,940
| -26% | -$301K | ﹤0.01% | 3414 |
|
|
2022
Q2 | $1.36M | Sell |
26,512
-27,186
| -51% | -$1.41M | 0.01% | 2205 |
|
|
2022
Q1 | $3.96M | Buy |
53,698
+28,836
| +116% | +$2.57M | 0.03% | 911 |
|
|
2021
Q4 | $3.56M | Buy |
24,862
+22,208
| +837% | +$3.82M | 0.03% | 889 |
|
|
2021
Q3 | $550K | Sell |
2,654
-10,600
| -80% | -$2.34M | 0.01% | 1971 |
|
|
2021
Q2 | $2.81M | Buy |
13,254
+8,379
| +172% | +$1.54M | 0.03% | 871 |
|
|
2021
Q1 | $884K | Sell |
4,875
-1,025
| -17% | -$204K | 0.01% | 1615 |
|
|
2020
Q4 | $658K | Sell |
5,900
-2,893
| -33% | -$307K | 0.01% | 1627 |
|
|
2020
Q3 | $953K | Buy |
8,793
+5,847
| +198% | +$712K | 0.01% | 1363 |
|
|
2020
Q2 | $246K | Buy |
+2,946
| New | +$113K | ﹤0.01% | 1944 |
|
|
2019
Q2 | – | Sell |
-4
| Closed | – | – | 2548 |
|
|
2019
Q1 | $0 | Sell |
4
-7,352
| -100% | -$232K | ﹤0.01% | 2367 |
|
|
2018
Q4 | $271K | Buy |
7,356
+6,312
| +605% | +$245K | 0.01% | 1353 |
|
|
2018
Q3 | $39K | Sell |
1,044
-5,670
| -84% | -$160K | ﹤0.01% | 1739 |
|
|
2018
Q2 | $180K | Buy |
6,714
+1,103
| +20% | +$37.3K | 0.01% | 1387 |
|
|
2018
Q1 | $236K | Buy |
+5,611
| New | +$225K | 0.01% | 1305 |
|
|
2016
Q4 | – | Sell |
-1,245
| Closed | -$52K | – | 1836 |
|
|
2016
Q3 | $52K | Buy |
+1,245
| New | +$161K | ﹤0.01% | 1566 |
|
|
2016
Q2 | – | Sell |
-2,774
| Closed | -$286K | – | 1825 |
|
|
2016
Q1 | $286K | Buy |
2,774
+2,632
| +1,854% | +$282K | 0.02% | 1011 |
|
|
2015
Q4 | $24K | Sell |
142
-2,850
| -95% | -$439K | ﹤0.01% | 1671 |
|
|
2015
Q3 | $423K | Buy |
+2,992
| New | +$671K | 0.02% | 1055 |
|
|
2015
Q2 | – | Sell |
-2,449
| Closed | -$405K | – | 1972 |
|
|
2015
Q1 | $405K | Buy |
+2,449
| New | +$398K | 0.02% | 1069 |
|
|
2014
Q4 | – | Sell |
-3,276
| Closed | -$273K | – | 1995 |
|
|
2014
Q3 | $273K | Buy |
+3,276
| New | +$296K | 0.02% | 1163 |
|
Other funds holding NVAX
SCM
S
Cubist Systematic Strategies's NVAX Position: Q3 2025 in Review
Cubist Systematic Strategies reduced its Novavax (NVAX) stake by 69% in Q3 2025, selling an estimated $3.83M and leaving 221,540 shares worth $1.92M. The position accounts for 0.01% of the portfolio, ranked #1593.
Cubist Systematic Strategies first reported a position in NVAX in Q3 2014 and has held it in 26 quarters since. The position peaked at $5.04M in Q4 2022. 249 funds tracked by Wall St. Rank hold NVAX as of Q3 2025.
- Cubist Systematic Strategies held 221,540 shares of Novavax worth $1.92M as of Q3 2025.
- Cubist Systematic Strategies sold 492,146 Novavax shares in Q3 2025, an estimated $3.83M.
- Novavax made up 0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #1593 holding.
- Cubist Systematic Strategies first reported a position in Novavax in Q3 2014 and has held it in 26 quarters since.
- Cubist Systematic Strategies's Novavax position peaked at $5.04M in Q4 2022.
- 249 funds tracked by Wall St. Rank held Novavax as of Q3 2025.
Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.